Videos

Dr Liaw discusses ways to measure response to treatment and what recent data regarding PSA kinetics has shown.

Dr Bobby Liaw talks about relationship between treatment duration, dosing and efficacy.

At 2022 ASCO GU, Toni K. Choueiri, MD, explained the data seen in the updated results from the KEYNOTE-564 trial for patients with renal cell carcinoma.

Drs Richter and Fanning discuss next steps and future directions in the management of patients with relapsed/refractory multiple myeloma.

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, spoke about how immunotherapy has influenced treatment for patients with bladder cancer.

Yelena Y. Janjigian, MD, spoke about using immunotherapy across settings to treat localized gastric cancer.

In the context of mobocertinib clinical data, experts consider factors that help them select therapy and manage therapy for patients with EGFR exon 20 insertion–positive mNSCLC.

Focused discussion on the safety profile of mobocertinib in platinum-pretreated EGFR exon 20 insertion–positive mNSCLC given data from the EXCLAIM cohort.

Axel Merseburger, MD, PhD, looked back on 2022 ASCO GU and the new data presented for the treatment of prostate cancer.

Yi-Bin Chen, MD, reviews the currently available FDA-approved therapies for the management of steroid-refractory chronic GvHD.

An expert in hematology-oncology comments on the importance of early detection and intervention of steroid-refractory chronic GvHD [graft-versus-host disease] and considers approaches to switching treatments.

Dr. Atish Choudhury discusses safety features to keep in mind when choosing androgen receptor pathway inhibitors.

A prostate cancer expert shares long-term data with androgen receptor pathway inhibitors in mCSPC.

Jorge E. Cortes, MD and Hagop Kantarjian, MD share a summary on ponatinib in CML and ALL and exploration of potential future studies.

Adverse events commonly associated with chemotherapies used to treat HER2-positive metastatic breast cancer, and recommendations to help equip patients with knowledge about what to expect during their treatment journey.

Erika Rich, a patient with HER2-positive metastatic breast cancer, explains why she opted to pursue a second opinion about her diagnosis and treatment options and proactively research her disease.

Dr. Liaw shares the role disease burden and other factors play in treatment selection.

Dr. Choudhury discusses treatment considerations and treatment options for mCSPC.

Experts summarize key points from routine clinical practice on use of ixazomib, lenalidomide, and dexamethasone (IRD) in patients with relapsed/refractory multiple myeloma.

Chung-Han Lee, MD, PhD, spoke about necessary research needed moving forward for patients with metastatic renal cell carcinoma.

Kohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.

Yelena Y. Janjigian, MD, spoke about using immunotherapy to treat localized gastric cancer.

Thomas Martin, MD, spoke about how the approval of ciltacabtagene autoleucel for patients with relapsed/refractory multiple myeloma may change the standard of care in this setting.

Ruben Mesa, MD, spoke about why pacritinib in the treatment of myelofibrosis is beneficial.

Shared insight on efficacy data with mobocertinib from the EXCLAIM cohort of patients with platinum-pretreated EGFR exon 20 insertion–positive mNSCLC.

Expert oncologists review data from the EXCLAIM cohort, which analyzed mobocertinib use in platinum-pretreated patients with EGFR exon 20 insertion–positive mNSCLC.

An expert in hematology/oncology comments on the importance of early detection and intervention of steroid-refractory chronic GvHD and considers approaches to switching treatments.

Yi-Bin Chen, MD, provides insight on common symptoms of GvHD (graft-versus-host disease), and shares tools for risk assessment and staging of the disease.

At 2022 ASCO GU, Toni K. Choueiri, MD, discussed the CLEAR study and how East Asian patients with renal cell carcinoma derived similar benefit with lenvatinib plus pembrolizumab as the overall trial population.

Thomas Martin, MD, spoke about how to increase response durability with ciltacabtagene autoleucel for patients with heavily pretreated multiple myeloma.